Adjunctive N-acetyl cysteine (NAC) may be efficacious in treating the depressive phase of bipolar disorder, new research suggests.
In an open-label study from Australian researchers presented here at the Ninth International Conference on Bipolar Disorder (ICBD), patients diagnosed with bipolar disorder and given 2000 mg of NAC in addition to their «treatment as usual» showed significantly lower symptom severity scores and increased functioning and quality-of-life scores.
«One of the biggest things I like is not only does [NAC] work symptomatically but it works functionally, which is just really helpful,» lead author Olivia Dean, PhD, from the Mental Health Research Institute and Deakin University School of Medicine in Victoria, Australia, told Medscape Medical News.
The investigators note that «this study encompasses a completely novel approach to the treatment of bipolar depression, focusing on established biomarkers to define novel therapeutic targets.»
Les mer: N-Acetyl Cysteine Effective for Bipolar Depression (Krever gratis registrering og innlogging på Medscape.com)
PsykNytt har ikke gjennomført noen systematisk kvalitetsvurdering av studien som omtales.
Disclaimer: Fotografiene i PsykNytt er illustrasjonsfoto, og personene på bildene har ingenting med sakene å gjøre.
Legg inn en kommentar